vs

Side-by-side financial comparison of FLANIGANS ENTERPRISES INC (BDL) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

FLANIGANS ENTERPRISES INC is the larger business by last-quarter revenue ($52.6M vs $33.4M, roughly 1.6× Ginkgo Bioworks Holdings, Inc.). On growth, FLANIGANS ENTERPRISES INC posted the faster year-over-year revenue change (4.6% vs -23.8%). FLANIGANS ENTERPRISES INC produced more free cash flow last quarter ($4.5M vs $-47.7M). Over the past eight quarters, FLANIGANS ENTERPRISES INC's revenue compounded faster (4.6% CAGR vs -6.2%).

Flanigans Enterprises Inc. is a U.S.-based hospitality company focused on the Florida market. It operates a chain of casual dining restaurants under the Flanigan's Seafood Bar and Grill brand, plus retail package liquor stores. Its key customer segments include local residents and regional tourists, offering affordably priced seafood, American comfort food and assorted beverages.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

BDL vs DNA — Head-to-Head

Bigger by revenue
BDL
BDL
1.6× larger
BDL
$52.6M
$33.4M
DNA
Growing faster (revenue YoY)
BDL
BDL
+28.4% gap
BDL
4.6%
-23.8%
DNA
More free cash flow
BDL
BDL
$52.2M more FCF
BDL
$4.5M
$-47.7M
DNA
Faster 2-yr revenue CAGR
BDL
BDL
Annualised
BDL
4.6%
-6.2%
DNA

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BDL
BDL
DNA
DNA
Revenue
$52.6M
$33.4M
Net Profit
$805.0K
Gross Margin
Operating Margin
3.2%
-211.9%
Net Margin
1.5%
Revenue YoY
4.6%
-23.8%
Net Profit YoY
1363.6%
EPS (diluted)
$0.43
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BDL
BDL
DNA
DNA
Q4 25
$52.6M
$33.4M
Q3 25
$50.0M
$38.8M
Q2 25
$51.9M
$49.6M
Q1 25
$53.4M
$48.3M
Q4 24
$50.0M
$43.8M
Q3 24
$45.4M
$89.0M
Q2 24
$48.8M
$56.2M
Q1 24
$48.1M
$37.9M
Net Profit
BDL
BDL
DNA
DNA
Q4 25
$805.0K
Q3 25
$896.0K
$-80.8M
Q2 25
$1.4M
$-60.3M
Q1 25
$2.7M
$-91.0M
Q4 24
$55.0K
Q3 24
$184.0K
$-56.4M
Q2 24
$1.1M
$-217.2M
Q1 24
$1.9M
$-165.9M
Operating Margin
BDL
BDL
DNA
DNA
Q4 25
3.2%
-211.9%
Q3 25
3.3%
-231.8%
Q2 25
5.5%
-132.1%
Q1 25
6.6%
-184.1%
Q4 24
1.5%
-236.3%
Q3 24
0.7%
-62.0%
Q2 24
4.4%
-396.7%
Q1 24
5.6%
-469.1%
Net Margin
BDL
BDL
DNA
DNA
Q4 25
1.5%
Q3 25
1.8%
-207.9%
Q2 25
2.7%
-121.6%
Q1 25
5.0%
-188.2%
Q4 24
0.1%
Q3 24
0.4%
-63.3%
Q2 24
2.3%
-386.4%
Q1 24
4.0%
-437.3%
EPS (diluted)
BDL
BDL
DNA
DNA
Q4 25
$0.43
$-1.41
Q3 25
$0.48
$-1.45
Q2 25
$0.75
$-1.10
Q1 25
$1.45
$-1.68
Q4 24
$0.03
$-1.91
Q3 24
$0.11
$-1.08
Q2 24
$0.60
$-4.23
Q1 24
$1.04
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BDL
BDL
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$66.0M
$508.6M
Total Assets
$142.1M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BDL
BDL
DNA
DNA
Q4 25
$422.6M
Q3 25
$495.5M
Q2 25
$732.0K
$559.4M
Q1 25
$244.0K
$325.3M
Q4 24
$561.6M
Q3 24
$616.2M
Q2 24
$730.4M
Q1 24
$840.4M
Total Debt
BDL
BDL
DNA
DNA
Q4 25
Q3 25
$20.9M
Q2 25
Q1 25
Q4 24
Q3 24
$22.2M
Q2 24
Q1 24
Stockholders' Equity
BDL
BDL
DNA
DNA
Q4 25
$66.0M
$508.6M
Q3 25
$65.2M
$559.8M
Q2 25
$64.3M
$613.0M
Q1 25
$64.0M
$647.4M
Q4 24
$61.6M
$716.1M
Q3 24
$61.2M
$797.9M
Q2 24
$61.3M
$833.1M
Q1 24
$61.1M
$987.3M
Total Assets
BDL
BDL
DNA
DNA
Q4 25
$142.1M
$1.1B
Q3 25
$140.6M
$1.2B
Q2 25
$140.7M
$1.2B
Q1 25
$143.3M
$1.3B
Q4 24
$146.9M
$1.4B
Q3 24
$142.1M
$1.5B
Q2 24
$143.1M
$1.6B
Q1 24
$144.4M
$1.6B
Debt / Equity
BDL
BDL
DNA
DNA
Q4 25
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
0.36×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BDL
BDL
DNA
DNA
Operating Cash FlowLast quarter
$4.9M
$-47.7M
Free Cash FlowOCF − Capex
$4.5M
$-47.7M
FCF MarginFCF / Revenue
8.5%
-142.8%
Capex IntensityCapex / Revenue
0.9%
0.0%
Cash ConversionOCF / Net Profit
6.14×
TTM Free Cash FlowTrailing 4 quarters
$2.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BDL
BDL
DNA
DNA
Q4 25
$4.9M
$-47.7M
Q3 25
$3.4M
$-31.6M
Q2 25
$1.4M
$-40.3M
Q1 25
$-2.0M
$-51.5M
Q4 24
$7.7M
$-42.4M
Q3 24
$-103.5M
Q2 24
$3.1M
$-84.4M
Q1 24
$-89.3M
Free Cash Flow
BDL
BDL
DNA
DNA
Q4 25
$4.5M
$-47.7M
Q3 25
$2.4M
Q2 25
$-1.8M
$-40.3M
Q1 25
$-3.0M
$-59.1M
Q4 24
$7.0M
$-56.1M
Q3 24
$-118.6M
Q2 24
$2.2M
$-111.4M
Q1 24
$-96.0M
FCF Margin
BDL
BDL
DNA
DNA
Q4 25
8.5%
-142.8%
Q3 25
4.9%
Q2 25
-3.4%
-81.2%
Q1 25
-5.5%
-122.4%
Q4 24
13.9%
-128.0%
Q3 24
-133.2%
Q2 24
4.5%
-198.2%
Q1 24
-252.9%
Capex Intensity
BDL
BDL
DNA
DNA
Q4 25
0.9%
0.0%
Q3 25
1.9%
0.0%
Q2 25
6.1%
0.1%
Q1 25
1.8%
15.8%
Q4 24
1.5%
31.3%
Q3 24
16.9%
Q2 24
1.8%
48.1%
Q1 24
17.7%
Cash Conversion
BDL
BDL
DNA
DNA
Q4 25
6.14×
Q3 25
3.75×
Q2 25
1.02×
Q1 25
-0.73×
Q4 24
140.02×
Q3 24
Q2 24
2.75×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BDL
BDL

Restaurant Food Sales$30.9M59%
Package Store Sales$13.3M25%
Restaurant Bar Sales$7.9M15%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons